Treatment for Eradication of Helicobacter pylori Infection among Chronic Hepatitis C Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Helicobacter pylori infection causes gastritis,peptic ulcers and gastric malignancies, and its eradication has been advocated by many groups. We determined the H. pylori carrier status and eradication rates of patients with chronic hepatitis C virus (HCV) infection. Methods: In total,76 chronically HCV-infected patients were enrolled for comparison with 228 HCV-noninfected, age- and sex-matched controls. H. pylori infection was confirmed by H. pylori antibody and urea breath testing. Results: The H. pylori infection rate was significantly higher for HCV-infected patients (67of 76, 88.2%) than for HCV-noninfected controls (158 of 228, 69.3%). Endoscopic fi ndings showed that the rates of gastric ulcers and gastritis were significantly higher for the 67 HCV-infected patients with H. pylori infection (34.3% and 77.6%) than for the 158 HCV-noninfected controls with H. pylori infection (15.2% and 57.6%). Treatment to eradicate H. pylori had a signifi cantly higher success rate for HCV-infected patients (61 of 67, 91.0%) than for HCV-noninfected controls (115 of 158, 72.8%). Conclusions: The markedly high H. pylori eradication rate observed in this study shows that eradication of H. pylori holds promise for the improvement of the long-term health condition of patients with chronic HCV infection.
Abstract
Background/Aims: Helicobacter pylori infection causes gastritis,peptic ulcers and gastric malignancies, and its eradication has been advocated by many groups. We determined the H. pylori carrier status and eradication rates of patients with chronic hepatitis C virus (HCV) infection. Methods: In total,76 chronically HCV-infected patients were enrolled for comparison with 228 HCV-noninfected, age- and sex-matched controls. H. pylori infection was confirmed by H. pylori antibody and urea breath testing. Results: The H. pylori infection rate was significantly higher for HCV-infected patients (67of 76, 88.2%) than for HCV-noninfected controls (158 of 228, 69.3%). Endoscopic fi ndings showed that the rates of gastric ulcers and gastritis were significantly higher for the 67 HCV-infected patients with H. pylori infection (34.3% and 77.6%) than for the 158 HCV-noninfected controls with H. pylori infection (15.2% and 57.6%). Treatment to eradicate H. pylori had a signifi cantly higher success rate for HCV-infected patients (61 of 67, 91.0%) than for HCV-noninfected controls (115 of 158, 72.8%). Conclusions: The markedly high H. pylori eradication rate observed in this study shows that eradication of H. pylori holds promise for the improvement of the long-term health condition of patients with chronic HCV infection.
참고문헌 (40)
- Cave DR, "How is Helicobacter pylori transmitted", Gastroenterology, 113(6 Suppl), pp.S9~S14 (1997)
- Fujimoto Y, "Intrafamilial transmission of Helicobacter pylori among the population of endemic areas in Japan", Helicobacter, 12, pp.170~176 (2007)
- Furusyo N, "Rapidly growing primary gastric B-cell lymphoma after eradication of Helicobacter pylori", Intern Med, 38, pp.796~799 (1999)
- Dooley CP, "Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomaticpersons", N Engl J Med, 321, pp.1562~1566 (1989)
- World Health Organization, International Agency for Research on Cancer (IARC), "IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 61, Schistosomes, liver flukes and Helicobacter pylori", pp.177~240 (1994), IARC
- Graham DY, "Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model", Gastroenterology, 113, pp.1983~1991 (1997)
- Asaka M, "Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population", Gastroenterology, 102, pp.760~766 (1992)
- Rothenbacher D, "Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications", Microbes Infect, 5, pp.693~703 (2003)
- Bardhan PK, "Epidemiological features of Helicobacter pylori infection in developing countries", Clin Infect Dis, 25, pp.973~978 (1997)
- Everhart JE, "Recent developments in the epidemiology of Helicobacter pylori", Gastroenterol Clin North Am, 29, pp.559~578 (2000)
- Kawai K, "Natural history and epidemiologic studies of peptic ulcer disease in Japan", Gastroenterology, 96(2 Pt 2 Suppl), pp.581~585 (1989)
- Kawai K, "Epidemiological aspects of peptic ulcers in Japan", Amsterdam Excerpta Medica, 22, pp.3~9 (1987)
- Asaka M, "Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition", Helicobacter, 15, pp.1~20 (2010)
- Sonnenberg A, "Factors which influence the incidence and course of peptic ulcer", Scand J Gastroenterol Suppl, 155, pp.119~140 (1988)
- Van der Hulst RW, "Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study", Gastroenterology, 113, pp.1082~1086 (1997)
- Hayashi J, "A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia", J Infect Dis, 181, pp.1523~1527 (2000)
- Siringo S, "Peptic ulcer and its course in cirrhosis: an endoscopic and clinical prospective study", J Hepatol, 22, pp.633~641 (1995)
- Bedossa P, "Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C", Hepatology, 20, pp.15~20 (1994)
- Umemura T, "Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C", J Viral Hepat, 14, pp.48~54 (2007)
- El-Masry S, "Helicobacter pylori and Hepatitis C virus coinfection in Egyptian patients", J Glob Infect Dis, 2, pp.4~9 (2010)
- Hayashi J, "Transmission of hepatitis C virus by health care workers in a rural area of Japan", Am J Gastroenterol, 90, pp.794~799 (1995)
- Nakashima K, "Sexual transmission of hepatitis C virus among female prostitutes and patients with sexually transmitted diseases in Fukuoka, Kyushu, Japan", Am J Epidemiol, 136, pp.1132~1137 (1992)
- Gruener NH, "Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus", J Virol, 75, pp.5550~5558 (2001)
- Blanton RE, "Population-based differences in Schistosoma mansoni- and hepatitis C-induced disease", J Infect Dis, 185, pp.1644~1649 (2002)
- Hartzog GA, "Evidence that Spt4, Spt5, and Spt6 control transcription elongation by RNA polymerase II in Saccharomyces cerevisiae", Genes Dev, 12, pp.357~369 (1998)
- Andrulis ED, "High-resolution localization of Drosophila Spt5 and Spt6 at heat shock genes in vivo: roles in promoter proximal pausing and transcription elongation", Genes Dev, 14, pp.2635~2649 (2000)
- D’Elios MM, "Different cytokine profile and antigen-specificity repertoire in Helicobacter pylorispecific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer", Eur J Immunol, 27, pp.1751~1755 (1997)
- McCormack TT, "Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy", Gut, 26, pp.1226~1232 (1985)
- Goodwin CS, "Helicobacter pylori infection", Lancet, 349, pp.265~269 (1997)
- Ofman JJ, "Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences", Ann Intern Med, 126, pp.280~297 (1997)
- Unge P, "Review of Helicobacter pylori eradication regimens", Scand J Gastroenterol Suppl, 215, pp.74~81 (1996)
- Cederbrant G, "Proposed mechanism for metronidazole resistance in Helicobacter pylori", J Antimicrob Chemother, 29, pp.115~120 (1992)
- Peterson WL, "Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial", Am J Gastroenterol, 88, pp.1860~1864 (1993)
- Kato M, "Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan", Antimicrob Agents Chemother, 44, pp.2214~2216 (2000)
- Sekiguchi M, "Localization of a novel proton pump inhibitor, lansoprazole, in the gastric mucosa of the rat: a radio autographic study", Acta Histochem Cytochem, 25, pp.405~410 (1992)
- de Morais SM, "The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans", J Biol Chem, 269, pp.15419~15422 (1994)
- Furuta T, "CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans", Clin Pharmacol Ther, 65, pp.552~561 (1999)
- Xie HG, "Evidence for the effect of gender on activity of (S)-mephenytoin 4’-hydroxylase (CYP2C19) in a Chinese population", Pharmacogenetics, 7, pp.115~119 (1997)
- Andersson T, "Omeprazole drug interaction studies", Clin Pharmacokinet, 21, pp.195~212 (1991)
- Horiki N, "Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan", Helicobacter, 14, pp.86~90 (2009)